A Phase 4 interventional study of Boostrix™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 1 site in Australia. Open to participants aged 28 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.
Among the 22 studies testing boostrix in Tetanus, this one is the 17th largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 4, and was the 9th registered.
318 studies on the registry are indexed under Tetanus; 29 are open to participants now.
Browse Tetanus studies →2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 28 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2007.
This study's enrollment of 203 is below the median of 418 across 280 interventional studies indexed under Tetanus.
Median enrollment 554 across the 22 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 77th largest by enrollment of the 98 interventional ones that give a count, is one of 7 that started in 2007, is one of 22 in phase 4, and was the 44th registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing boostrix in Tetanus, from their registry updates:
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a previous clinical study (NCT01267058). Only subjects who received the booster vaccination in a previous clinical study are eligible for participation in this study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
No new recruitment will be performed in this booster phase (see inclusion criteria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
Biological: Boostrix™
Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
Biological: Boostrix™
Intramuscular injection, 1 dose
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (≥) 0.1 International Units Per Milliliter (IU/mL)
Cut-off values defining seroprotected subjects against anti-DT/anti-TT were greater than or equal to (≥) 0.1 IU/mL as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA). The analysis was performed and presents results only for subjects who in the previous study NCT01267058, had received the Boostrix™ vaccine as first booster.
Time frame: One month after the booster vaccination [PI(M1)]
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Equal to or Above Cut-off Values
Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and (≥) 1 IU/mL.
Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Number of Subjects With Anti-DT and Anti-TT Antibody Concentrations Equal to or Above Cut-off Values
Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and ≥ 1 IU/mL. This endpoint presents results for subjects included in the ATP cohort for antibody persistence.
Time frame: Prior (PRE) to booster vaccination
Anti-DT and Anti-TT Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
Time frame: Prior to the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
Time frame: Prior the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
Time frame: Prior the booster vaccination
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.
Time frame: Prior the booster vaccination
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL)
Time frame: Prior the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA.
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
Time frame: Prior to the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
Time frame: Prior to the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
Time frame: One month after the booster vaccination
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥ 0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
Time frame: One month after the booster vaccination
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies
Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.
Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).
Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN
Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations \< 5 El.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations ≥5 El.U/mL).
Time frame: One month after the booster vaccination
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
Time frame: During the 4-day (Day 0-3) follow-up period after booster vaccination
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
Time frame: During the 4-day (Day 0-3) follow-up period after booster vaccination
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
Time frame: During the 31-day (Day 0-30) follow-up period after booster vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
Time frame: Following the booster vaccination
| Milestone | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Started | 164 | 39 |
| Completed | 164 | 39 |
| Not completed | 0 | 0 |
Cut-off values defining seroprotected subjects against anti-DT/anti-TT were greater than or equal to (≥) 0.1 IU/mL as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA). The analysis was performed and presents results only for subjects who in the previous study NCT01267058, had received the Boostrix™ vaccine as first booster.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-DT ≥ 0.1 PI(M1) | 151 | 35 |
| Anti-TT ≥ 0.1 PI(M1) | 153 | 35 |
Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and (≥) 1 IU/mL.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-DT ≥ 0.1 IU/mL, PRE | 95 | 20 |
| Anti-DT ≥ 0.1 IU/mL, PI(M1) | 151 | 35 |
| Anti-DT ≥ 1 IU/mL, PRE | 24 | 7 |
| Anti-DT ≥ 1 IU/mL, PI(M1) | 106 | 23 |
| Anti-TT ≥ 0.1 IU/mL, PRE | 145 | 30 |
| Anti-TT ≥ 0.1 IU/mL, PI(M1) | 153 | 35 |
| Anti-TT ≥ 1 IU/mL, PRE | 90 | 23 |
| Anti-TT ≥ 1 IU/mL, PI(M1) | 153 | 35 |
Concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
| IU/mL | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-DT, PRE | 0.200 (0.161 to 0.249) | 0.233 (0.138 to 0.392) |
| Anti-DT, PI(M1) | 1.889 (1.547 to 2.306) | 1.605 (1.111 to 2.319) |
| Anti-TT, PRE | 1.026 (0.859 to 1.224) | 0.845 (0.538 to 1.327) |
| Anti-TT, PI(M1) | 6.927 (6.204 to 7.735) | 5.933 (4.768 to 7.384) |
Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and ≥ 1 IU/mL. This endpoint presents results for subjects included in the ATP cohort for antibody persistence.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-DT ≥ 0.1 IU/mL, PRE | 102 | 22 |
| Anti-DT ≥ 1 IU/mL, PRE | 25 | 7 |
| Anti-TT ≥ 0.1 IU/mL, PRE | 152 | 32 |
| Anti-TT ≥ 1 IU/mL, PRE | 95 | 25 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
| IU/mL | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-DT, PRE | 0.208 (0.168 to 0.257) | 0.235 (0.144 to 0.384) |
| Anti-TT, PRE | 1.031 (0.868 to 1.225) | 0.898 (0.581 to 1.386) |
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - ELISA | 56 | 14 |
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test | 16 | 4 |
Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-PT | 137 | 23 |
| Anti-FHA | 159 | 37 |
| Anti-PRN | 151 | 33 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL)
| EL.U/mL | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-PT | 13.9 (11.9 to 16.2) | 8.3 (5.9 to 11.7) |
| Anti-FHA | 137.2 (116.7 to 161.3) | 115.6 (80.2 to 166.5) |
| Anti-PRN | 56.6 (44.2 to 72.4) | 50.2 (27.9 to 90.4) |
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - ELISA. | 56 | 14 |
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test. | 16 | 4 |
Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - ELISA | 1 | 0 |
Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥ 0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test | 0 | — |
Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-PT, PRE | 131 | 22 |
| Anti-PT, PI(M1) | 152 | 35 |
| Anti-FHA, PRE | 152 | 35 |
| Anti-FHA, PI(M1) | 152 | 35 |
| Anti-PRN, PRE | 144 | 31 |
| Anti-PRN, PI(M1) | 153 | 34 |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).
| EL.U/mL | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-PT, PRE | 13.9 (11.9 to 16.2) | 8.4 (5.9 to 11.8) |
| Anti-PT, PI(M1) | 126.5 (109.9 to 145.6) | 120.8 (88.9 to 164.2) |
| Anti-FHA, PRE | 140.2 (118.9 to 165.4) | 119.3 (81.3 to 175.1) |
| Anti-FHA, PI(M1) | 615.3 (543.8 to 696.2) | 677.4 (513.7 to 893.2) |
| Anti-PRN, PRE | 56.2 (43.6 to 72.5) | 45.7 (24.9 to 83.7) |
| Anti-PRN, PI(M1) | 303.6 (259.6 to 355.0) | 370.7 (280.5 to 489.9) |
Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations \< 5 El.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations ≥5 El.U/mL).
| Participants | Boostrix I Group | Boostrix II Group |
|---|---|---|
| Anti-PT | 148 | 33 |
| Anti-FHA | 119 | 31 |
| Anti-PRN | 106 | 26 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
| Participants | Boostrix Pooled Group |
|---|---|
| Any Pain | 142 |
| Grade 3 Pain | 2 |
| Any Redness | 72 |
| Grade 3 Redness | 14 |
| Any Swelling | 66 |
| Grade 3 Swelling | 20 |
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
| Participants | Boostrix Pooled Group |
|---|---|
| Any Fatigue | 47 |
| Grade 3 Fatigue | 0 |
| Related Fatigue | 25 |
| Any Fever | 6 |
| Grade 3 Fever | 0 |
| Related Fever | 5 |
| Any Gastrointestinal symptom | 15 |
| Grade 3 Gastrointestinal symptom | 1 |
| Related Gastrointestinal symptom | 7 |
| Any Headache | 39 |
| Grade 3 Headache | 2 |
| Related Headache | 18 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
| Participants | Boostrix Pooled Group |
|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 35 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.
| Participants | Boostrix Pooled Group |
|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 0 |
Collected over Solicited symptoms: during the 4-day (Days 0-3) follow-up period post booster vaccination; Unsolicited AEs: during the 31-day (Days 0-30) follow-up period post booster vaccination; SAEs: during the entire study period (following booster vaccination).. Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix Pooled Group | 0/203 (0%) | 0/203 (0%) | 163/203 (80.3%) |
| Event | Boostrix Pooled Group |
|---|---|
| PainGeneral disorders | 142/203 |
| ErythemaSkin and subcutaneous tissue disorders | 72/203 |
| SwellingGeneral disorders | 66/203 |
| FatigueGeneral disorders | 47/203 |
| HeadacheNervous system disorders | 40/203 |
| Gastrointestinal disorderGastrointestinal disorders | 15/203 |
| Injection site pruritusGeneral disorders | 9/203 |
| PyrexiaGeneral disorders | 6/203 |
| Age, Continuous(Years) | Boostrix I Group | Boostrix II Group | Total |
|---|---|---|---|
| Mean | 50.1 ± 9.98 | 51.0 ± 8.70 | 50.27 ± 9.73 |
| Sex: Female, Male(Participants) | Boostrix I Group | Boostrix II Group | Total |
|---|---|---|---|
| Female | 107 | 33 | 140 |
| Male | 57 | 6 | 63 |
| Race and Ethnicity Not Collected(Participants) | Boostrix I Group | Boostrix II Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Nov 2007 to primary completion in Apr 2008, 5 months.
Results were first posted in Jan 2019, 10 years 8 months after primary completion. A results delay was requested in Sep 2009.
Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix